SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is actively discussed due to escalating geopolitical tensions, specifically new tariff threats against European economies related to Greenland, which has led to declines in overnight futures and global markets. The community is sharply divided, with many anticipating a significant market pullback, while others view it as a "buy the dip" opportunity, recalling historical recoveries from similar tariff-induced sell-offs. This divergence creates intense debate over whether current events will lead to a deeper correction or are merely temporary volatility before further upside.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as renewed tariff threats regarding Greenland trigger market volatility, with the community sharply divided between those anticipating a significant correction and "buy the dip" proponents. Investors are weighing escalating geopolitical tensions and rising treasury yields against historical market resilience and expectations for a robust tech earnings season.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending with significant bullish momentum following multiple analyst price target upgrades and a notable insider stock purchase, signaling strong confidence. Community discussions highlight an unprecedented and accelerating memory chip shortage, driven by explosive AI demand, which positions Micron as a critical, sold-out supplier of high-bandwidth memory. The company's strategic expansion in manufacturing, including new megafabs, further underpins the widespread belief in its sustained growth trajectory amidst the AI buildout.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as reports surface that Chinese customs have blocked H200 chip shipments, causing suppliers to pause production and sparking immediate market uncertainty. While some investors are reacting to the dip, many in the community view this as a buying opportunity, citing NVIDIA's robust long-term demand for its advanced AI architectures like Blackwell and Rubin. This geopolitical tension underscores the complex landscape for AI chip sales, even as analysts largely maintain bullish outlooks on NVIDIA's foundational role in global AI infrastructure.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin (APP) is trending due to a sharp price decline, which the community is hotly debating as either market manipulation around options expiration and a circulating short report, or broader ad-tech concerns like OpenAI's entry into advertising. Amid this volatility, bullish investors highlight AppLovin's robust AI-powered Axon platform and strong profitability as a compelling dip-buying opportunity, contrasting with those fearing continued weakness despite recent analyst upgrades.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Natural Gas prices are surging dramatically, driven by widespread forecasts for an intense Arctic blast across the US, with many in the community anticipating a significant short squeeze and a substantial gap-up for BOIL when markets open. Traders are actively debating whether these substantial gains will hold, given the highly volatile nature of leveraged natural gas ETFs like BOIL.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending with high investor enthusiasm following international approvals for its Anktiva treatment in both lung and bladder cancers, notably a first-in-world non-chemo combo for lung cancer from Saudi Arabia. This significant progress, coupled with reported substantial revenue growth, is generating widespread community discussion about the company's transformative potential in oncology and fueling considerable short squeeze speculation due to high short interest. Investors are closely monitoring further global regulatory developments and anticipating a paradigm shift in cancer treatment as Dr. Patrick Soon-Shiong actively promotes the company's innovative "BioShield" platform.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF (UVIX) is seeing intense discussion as escalating geopolitical tensions, from US actions in Venezuela and Greenland to EU tariff disputes and potential escalations with Iran and China, fuel expectations for a market-wide fear spike. Traders are actively positioning for a major upward move in volatility, leveraging UVIX for short-term hedges while widely acknowledging its pronounced decay characteristics make it unsuitable for extended holding.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst widespread discussion surrounding former President Trump's controversial geopolitical moves, specifically his asserted interest in Greenland and proposed tariffs on European allies, which many observers link to a past Nobel Peace Prize snub. Community perspectives are sharply divided, with intense debate on the potential market implications of these actions, reflecting broader concerns about global stability and U.S. foreign policy.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to a recently executed term sheet for a joint venture with a Saudi industrial conglomerate to build a rare earth processing facility, which notably secures 100% offtake for its Tanbreez project. The community is highly engaged in discussions surrounding Greenland's strategic importance for critical minerals, anticipating further updates and potential significant catalysts from upcoming corporate communications. This reinforces CRML's position in global efforts to diversify strategic mineral supply chains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Petros Pharmaceuticals sank to an all-time low on Wednesday after the company enacted a 1-for-25 reverse stock split, triggering a wave of retail investor chatter and raising fresh concerns about its Nasdaq listing status.The split, which became effective after markets closed Wednesday, aimed to lift Petros’ share price above Nasdaq’s $1 minimum bid requirement.&nbsp;While the maneuver shrank the company’s outstanding share count from roughly 53.5 million to about 2.14 million, it failed to stabilize investor sentiment.&nbsp;Shares tumbled more than 30% intraday Thursday, hitting a split-adjusted low of $0.012 — the stock’s lowest level since its 2020 debut.Despite the steep sell-off, sentiment among retail investors turned “extremely bullish” on Stocktwits amid “extremely high” message volume.One user said, “Given the incentive to exercise at no cost, they may use the remaining shares to drive the price down further,” adding that volume needed to hit at least 30 million before considering a position.&nbsp;<stembedurl>https://stocktwits.com/basijedal/message/613198834</stembedurl>Another said the reverse split “might actually be positive,” citing the post-split price as potentially attractive to speculators. “It probably will still be volatile and could go up,” they added.<stembedurl>https://stocktwits.com/1Black/message/613194524</stembedurl>The steep decline comes as Petros continues to face the risk of delisting from the Nasdaq Capital Market, after previously receiving a noncompliance notice related to minimum stockholders' equity requirements.In parallel, the company is pivoting from its legacy men’s health products toward regulatory-aligned digital health solutions.&nbsp;Petros is developing a software-as-a-medical-device platform that leverages AI and big data to assist pharmaceutical companies with converting prescription drugs to over-the-counter status.&nbsp;Management positioned this strategy as well-timed following President Trump’s April 15 executive order titled&nbsp;“Lowering Drug Prices by Once Again Putting Americans First”—a policy Petros says supports its market transition.“This Executive Order supports the notion that the under-insured and the American population at large will benefit from expanded access to certain drugs,” said Chief Commercial Officer Fady Boctor.&nbsp;He added that Petros’ platform could unlock partnerships with pharmaceutical firms aiming to extend their product lifecycles and reduce drug prices.But questions remain about the company’s financial health.&nbsp;For the year ended Dec. 31, 2024, Petros reported revenue of $5.11 million, down from $5.82 million in 2023.&nbsp;Net losses widened to $14.32 million from $8.16 million, even as loss per share narrowed to $3.34 from $6.35 due to a higher share count.Petros shares have tumbled over 99.9% year-to-date, far underperforming the Dow Jones, down 4.1%, the S&amp;P 500, down 5.1%, and the Nasdaq, down 1.6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Traders work on the floor of the New York Stock Exchange during morning trading on April 30, 2025 in New York City. (Photo by Michael M. Santiago/Getty Images)

Petros Pharma Stock Plunges To Record Low On 1-For-25 Reverse Split, But Retail Optimism Lingers

Petros Pharmaceuticals hit an all-time low after a 1-for-25 reverse stock split, drawing bullish retail chatter even as delisting risks and mounting losses weighed on the stock.

Equity

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharma co-vigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, an FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Current Price	$0.008
Prev Close	$0.0084
Open	$0.0073
Dividend Yield	0.00%
50-Day Moving Average	$0.0118
Beta	0.54
Avg. Volume	271,493.05
PE Ratio	0.00

52-Week High	$16.25
52-Week Low	$0.0017
Market Capitalization	$338,978.00
EPS (Annual)	-$83.47
Price to Book	0.10
Revenue Per Employee	$284,002.39
Enterprise Value/EBITDA	N/A

PTPI
Petros Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest PTPI News

PTPIPetros Pharmaceuticals Inc